Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

Neuroradiology

Volumn 54, Issue 12, 2012, Pages 1331-1339

  Winston, Alan ^a   Duncombe, Chris ^b   Li, Patrick C K ^c   Gill, John M ^d   Kerr, Stephen J ^b,e   Puls, Rebekah L ^e   Taylor Robinson, Simon D ^a   Emery, Sean ^e   Cooper, David A ^e  

^a ST MARY S HOSPITAL   (United Kingdom)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d Calgary Regional Health Authority   (Canada)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral; Cerebral; HIV; MRS

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLINE; CREATINE; INOSITOL;

ADULT; ANTIBODY DETECTION; ARTICLE; ASIAN; BASAL GANGLION; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF HIGHER CEREBRAL FUNCTION; ETHNICITY; FEMALE; GRAY MATTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE ANALYSIS; MALE; METABOLITE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84874435823     PISSN: 00283940     EISSN: 14321920     Source Type: Journal    
DOI: 10.1007/s00234-012-1061-5     Document Type: Article

References (53)

1. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13(10):1249-1253
2. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G (2009) Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharm 4(2):163-174
3. Liner KJ 2nd, Hall CD, Robertson KR (2008) Effects of antiretroviral therapy on cognitive impairment. Curr HIV/AIDS Rep 5(2):64-71
4. Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G (2001) Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 28(1):19-27
5. Garvey LJ, Yerrakalva D, Winston A (2009) Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. AIDS Res Hum Retroviruses 25(8):765-769
6. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, Lam M, Myers H, Wright MJ, Foley J (2009) Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 17(4):281-290
7. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Vlassi C, Piselli P, Visco-Comandini U, Quartuccio ME, Larussa D, Pucillo L, Petrosillo N, Ippolito G, Antinori A, Narciso P (2004) Neurocognitive Impairment and Survival in HIV-Positive Patients Treated with HAART: Results from an Urban Observational Cohort. In: 11th Conference on Retruviruses and Opportunistic Infections, San Fransisco, CA, February 2004
8. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N (2004) Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63(5):822-827
9. Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, Paul R, Shikuma C, Sacktor N (2006) Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-The Hawaii Aging with HIV Cohort. J Neurovirol 12(5):387-391
10. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52(1):56-63
11. Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ, Dore GJ (2007) Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 8(8):520-528
12. Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller EN (1999) Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53(4):782-789
13. Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, Shepard JK, Beecham M, Miller RF, Weller IV et al (1993) Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 188(1):119-124
14. Paley M, Wilkinson ID, Hall-Craggs MA, Chong WK, Chinn RJ, Harrison MJ (1995) Short echo time proton spectroscopy of the brain in HIV infection/AIDS. Magn Reson Imaging 13(6):871-875
15. Lopez-Villegas D, Lenkinski RE, Frank I (1997) Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 94(18):9854-9859
16. Paul RH, Yiannoutsos CT, Miller EN, Chang L, Marra CM, Schifitto G, Ernst T, Singer E, Richards T, Jarvik GJ, Price R, Meyerhoff DJ, Kolson D, Ellis RJ, Gonzalez G, Lenkinski RE, Cohen RA, Navia BA (2007) Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 19(3):283-292
17. Wiley CA, Masliah E, Morey M, Lemere C, DeTeresa R, Grafe M, Hansen L, Terry R (1991) Neocortical damage during HIV infection. Ann Neurol 29(6):651-657
18. Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, McArthur JC, Trapp BD (1993) Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34(3):339-350
19. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373(9672):1352-1363
20. Clumeck N, Pozniak A, Raffi F (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 9(2):65-71
21. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. At: http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 9, 2009
22. Gazzard BG (2008) British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 9(8):563-608
23. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355(22):2283-2296
24. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A (2007) Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 21(13):1717-1721
25. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R (2008) Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197(8):1133-1144
26. Cooper DA, Group AS (2009) Safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomised, open-label study. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009
27. Yiannoutsos CT, Ernst T, Chang L, Lee PL, Richards T, Marra CM, Meyerhoff DJ, Jarvik JG, Kolson D, Schifitto G, Ellis RJ, Swindells S, Simpson DM, Miller EN, Gonzalez RG, Navia BA (2004) Regional patterns of brain metabolites in AIDS dementia complex. NeuroImage 23(3):928-935
28. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D (2001) Java-based graphical user interface for the MRUI quantitation package. Magma 12(2-3):141-152
29. 1H human brain spectra by LCModel and AMARES. Magn Reson Med 51(5):904-912
30. Paul RH, Ernst T, Brickman AM, Yiannoutsos CT, Tate DF, Cohen RA, Navia BA (2008) Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc 14(5):725-733
31. Lawrence DM, Major EO (2002) HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect 4(3):301-308
32. Everall IP, Hansen LA, Masliah E (2005) The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 8(1-2):51-61
33. Corasaniti MT, Bagetta G, Rotiroti D, Nistico G (1998) The HIV envelope protein gp120 in the nervous system: interactions with nitric oxide, interleukin-1beta and nerve growth factor signalling, with pathological implications in vivo and in vitro. Biochem Pharmacol 56(2):153-156
34. Kruman II, Nath A, Mattson MP (1998) HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154(2):276-288
35. Smith TW, DeGirolami U, Henin D, Bolgert F, Hauw JJ (1990) Human immunodeficiency virus (HIV) leukoencephalopathy and the microcirculation. J Neuropathol Exp Neurol 49(4):357-370
36. Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A, Avison MJ (2000) Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 54(4):921-926
37. Berger JR, Nath A (1997) HIV dementia and the basal ganglia. Intervirology 40(2-3):122-131
38. van Gelder W, Huijskes-Heins MI, Cleton-Soeteman MI, van Dijk JP, van Eijk HG (1998) Iron uptake in blood-brain barrier endothelial cells cultured in iron-depleted and iron-enriched media. J Neurochem 71(3):1134-1140
39. Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 16(3):285-299
40. Taylor-Robinson SD, Oatridge A, Hajnal JV, Burroughs AK, McIntyre N, deSouza NM (1995) MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metab Brain Dis 10(2):175-188
41. Jordan BD, Navia BA, Petito C, Cho ES, Price RW (1985) Neurological syndromes complicating AIDS. Front Radiat Ther Oncol 19:82-87
42. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E (1999) Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 52(1):100-108
43. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG (1996) Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology 46(3):783-788
44. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E (2002) Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. NeuroImage 17(3):1638-1648
45. Cox IJ (1996) Development and applications of in vivo clinical magnetic resonance spectroscopy. Prog Biophys Mol Biol 65(1-2):45-81
46. 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58(22):1929-1935
47. Winston A, Garvey L, Scotney E, Yerrakalva D, Allsop JM, Thomson EC, Grover VP, Main J, Cox JI, Wylezinska M, Taylor-Robinson SD (2010) Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat 17:419-426
48. Tarasow E, Wiercinska-Drapalo A, Kubas B, Dzienis W, Orzechowska- Bobkiewicz A, Prokopowicz D, Walecki J (2003) Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients. Acta Radiol 44(2):206-212
49. Suwanwelaa N, Phanuphak P, Phanthumchinda K, Suwanwela NC, Tantivatana J, Ruxrungtham K, Suttipan J, Wangsuphachart S, Hanvanich M (2000) Magnetic resonance spectroscopy of the brain in neurologically asymptomatic HIV-infected patients. Magn Reson Imaging 18(7):859-865
50. Jarvik JG, Lenkinski RE, Saykin AJ, Jaans A, Frank I (1996) Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 13(3):247-253
51. Lentz MR, Kim WK, Kim H, Soulas C, Lee V, Venna N, Halpern EF, Rosenberg ES, Williams K, Gonzalez RG (2011) Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 17(3):220-229
52. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD (2001) Evidence for a cerebral effect of the hepatitis C virus. Lancet 358(9275):38-39
53. Marcondes MC, Flynn C, Huitron-Rezendiz S, Watry DD, Zandonatti M, Fox HS (2009) Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 23(10):1187-1195